Compounds of the general formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Mixture of bisphosphites having an open and a closed outer unit and the use thereof as a catalyst mixture in hydroformylation.

Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.

Polyolefin compositions comprising i) a polyolefin, ii) one or more phosphorus- containing benzofuranone compounds and iii) one or more hindered amine light stabilizers are provided excellent protection against discoloration and enhanced thermal stability during melt processing as exhibited by improved retention of molecular weight and maintenance of polymer molecular architecture.

Provided are: a nucleating agent capable of simultaneously improving the thermal stability and the transparency of a polyolefin resin; a polyolefin-based resin composition containing the same; and a molded article of the composition. The nucleating agent contains a compound represented by Formula (1) below where R.sup.1 to R.sup.4 each independently represent a hydrogen atom or a linear or branched alkyl group having 1 to 9 carbon atoms; R.sup.5 represents an alkanediyl group having 1 to 4 carbon atoms; and M represents a hydrogen atom or a sodium atom. In this nucleating agent, the mass ratio of phosphorus atoms and sodium atoms, P/Na, is in a range of 1.200 to 1.500.

##STR00001##

Provided are a 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-based monophosphine ligand and intermediates thereof, and preparation methods and uses of the same. The monophosphine ligand is a compound represented by formula I or formula I′, or an enantiomer, a raceme or a diastereoisomer thereof, including phosphonite ligands, phosphite ligands, phosphoramidite ester ligands, phosphoric acid and phosphonic amide. The monophosphine ligand is prepared with a known 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-7,7′-diol derivative as a raw material through a scheme in which the compound presented by formula II acts as an intermediate. The present disclosure provides a novel monophosphine ligand, which can be used as a ligand in a metal-catalysed organic reactions or in directly catalyzing an organic reaction, especially as a chiral monophosphine ligand widely used in many chiral catalytic reactions such as asymmetric addition, asymmetric hydrogenation, asymmetric coupling, and asymmetric allyl alkylation, having economic practicality and industrial application prospects. ##STR00001##

Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.

Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.

Provided herein are organophosphates and pharmaceutical compositions comprising said compounds.

Polyolefin compositions comprising i) a polyolefin, ii) one or more phosphorus-containing benzofuranone compounds and iii) one or more hindered phenolic antioxidants are provided excellent protection against discoloration and enhanced thermal stability during melt processing as exhibited by improved retention of molecular weight and maintenance of polymer molecular architecture.